title: Is (18)FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer?
authors.affiliation: Department of Nuclear Medicine, Saint-Louis Hospital, Paris, France. dgroheux@yahoo.fr.|University Paris-Diderot, INSERM/CNRS UMR944/7212, Paris, France. dgroheux@yahoo.fr.
authors.forename: David
authors.initials: D
authors.lastname: Groheux
authors.affiliation: Department of Nuclear Medicine, Bordeaux University Hospital, Bordeaux, France.
authors.forename: Elif
authors.initials: E
authors.lastname: Hindié
mesh_terms: D001692:Biological Transport; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism*; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism*; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*
chemical_list: D019788:Fluorodeoxyglucose F18; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen